Presentation is loading. Please wait.

Presentation is loading. Please wait.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Published byΛαμία Λούπης Modified over 5 years ago

Similar presentations

Presentation on theme: "Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin."— Presentation transcript:

1 Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin as First- Line Chemotherapy  Shanxian Guo, MD, Yonggang Liang, MD, Qinghua Zhou, MD  Journal of Thoracic Oncology  Volume 6, Issue 2, Pages (February 2011) DOI: /JTO.0b013e d8c Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Relative risk (RR) plot for response and hazard ratio (HR) plots for overall survival and progression-free survival. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e d8c) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 The pooled relative risk for toxicities.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e d8c) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin."

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,
Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Similar presentations

Ads by Google